Goal 2: Reduce Human Disease

To extend our knowledge of the pathobiology of heart, lung, blood, and sleep disorders and enable clinical investigations that advance the prediction, prevention, preemption, treatment, and cures of human disease.
(@chintamani.atreya)

Goal 2: Reduce Human Disease

Biorepository to facilitate epidemiologic studies of transfusion-transmitted diseases and validation of laboratory tests for don

There is a critical need for a proactive and coordinated effort to develop well-characterized biorepositories that can be used for epidemiologic studies of emerging infectious agents to expedite rapid implementation of donor screening tests for emerging pathogens and variants that pose a threat to the blood supply.

Voting

3 net votes
12 up votes
9 down votes
Active
(@nhlbiforumadministrator)

Goal 2: Reduce Human Disease

Nontuberculous mycobacterial (NTM) lung infections

The true prevalence of Nontuberculous mycobacterial (NTM) lung infections remains incompletely understood, however several aspects of NTM lung disease prevalence are becoming more clear. NTM lung disease is currently more common in the U.S. than TB (by a factor of 3) and has consistently been shown to be increasing in prevalence. When viewed in the context of likely universal environmental NTM exposure this increasing ...more »

Voting

1 net vote
1 up votes
0 down votes
Active
(@greg.martin)

Goal 2: Reduce Human Disease

Long-term pulmonary function in survivors of critical illness

Pulmonary function is known to suffer during the early recovery phases from critical illness, but the long-term patterns of recovery and associated consequences are uncertain. In addition, the clinical and molecular determinants of progressive deterioration or recovery of pulmonary function remain unknown.

Voting

4 net votes
7 up votes
3 down votes
Active
(@tsansone)

Goal 2: Reduce Human Disease

Critical Challenge

• One of the most important public health issues the Nation faces is the rising incidence of heart failure. HF incidence rates have risen faster than predicted. The prevalence will increase as better and more therapy becomes available. While heart failure is the biggest ticket item in the Medicare budget, the cost to society will increase more than it has already. But much HF can be prevented or onset prolonged. Investing ...more »

Voting

-3 net votes
4 up votes
7 down votes
Active
(@winters.jeffrey)

Goal 2: Reduce Human Disease

Lipid apheresis as adjunct therapy in peripheral vascular disease

What is the roll of inflammation and how does lipid apheresis alter inflammation in peripheral vascular disease when added to standard therapy and/or when used alone? Does lipid apheresis result in long-term improvement with reduced morbidity, mortality, and expense compared to standard therapy?

Voting

96 net votes
116 up votes
20 down votes
Active
(@dayam0)

Goal 2: Reduce Human Disease

Timing of post-cardiac arrest PCI

The majority of patients who are resuscitated from OHCA have a presumed cardiac etiology. One of the key interventions post cardiac arrest is to study the coronary circulation for underlying thrombosis. Some centers do this routinely but at other centers interventional cardiologists are hesitant to do this since the mortality rates are high and so affect their individual and institutional performance measures related ...more »

Voting

-1 net votes
2 up votes
3 down votes
Active